Dewpoint Therapeutics

Dewpoint Therapeutics leverages AI and condensate biology to develop novel therapeutics for a variety of disease indications, including oncology, virology, neuromuscular, and cardiopulmonary. The company’s biomolecule condensate approach makes use of condensates—compartments within cells that perform specific functions—to understand the root cause of a disease, thereby potentially identifying therapeutics for previously undruggable targets.

As of March 2024, the company had three internal targeted indications for oncology and neurodegenerative diseases. The company has plans to submit IND applications in 2025/2026.

Key customers and partnerships

The company has several partnerships with a number of Big Pharma companies, including Bayer (November 2019), to develop treatments for multiple cardiovascular and gynecological diseases; Merck (July 2020), to develop a treatment for human immunodeficiency virus (HIV); Pfizer (January 2021), to develop treatments for myotonic dystrophy type 1 (DM1); Novo Nordisk (March 2023) to treat insulin resistance and diabetic complications; Chemify (September 2023), to discover molecules targeting cancer and neurodegeneration; and Evotec to advance oncology programs (November 2023). 

Funding and financials

In February 2022, Dewpoint Therapeutics raised USD 150 million in a Series C funding round led by Softbank Vision Fund 2, with participation from other investors including Leaps by Bayer. The proceeds were earmarked for advancing the company’s drug development pipeline toward investigational new drug (IND) status and developing its platforms.